Eric Venker - Jul 28, 2025 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Signature
/s/ Tiago Girao, Attorney-in-Fact for Eric Venker
Stock symbol
IMVT
Transactions as of
Jul 28, 2025
Transactions value $
$0
Form type
4
Date filed
7/30/2025, 05:56 PM
Previous filing
Jul 23, 2025
Next filing
Aug 1, 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Venker Eric Chief Executive Officer, Director 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK /s/ Tiago Girao, Attorney-in-Fact for Eric Venker 2025-07-30 0001801917

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMVT Stock Option (right to buy) Award $0 +1.3M $0.00 1.3M Jul 28, 2025 Common Stock 1.3M $16.76 Direct F1
transaction IMVT Stock Option (right to buy) Award $0 +190K $0.00 190K Jul 28, 2025 Common Stock 190K $16.76 Direct F1
transaction IMVT Capped Value Appreciation Rights Award $0 +1.48M $0.00 1.48M Jul 28, 2025 Common Stock $14.46 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). 25% of the shares underlying the option shall vest on April 21, 2026, and the remaining shares subject to the option shall vest in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer or an affiliate on each such date.
F2 These capped value appreciation rights ("CVARs") will vest on the first date that each of (i) the Service Requirement, (ii) the Performance Requirement, and (iii) the Knock-in Requirement have been satisfied. The "Service Requirement" is satisfied as follows: (i) 25% of the CVARs vest on April 1, 2026; and (ii) the remaining 75% vests in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer or an affiliate on each such vesting date. The "Performance Requirement" is tied to the achievement of a specified clinical development activity at the Issuer. The "Knock-in Requirement" requires that the price of the Issuer's common stock at each applicable vesting date must be equal to or greater than $16.76 per share.
F3 Upon satisfaction of the vesting conditions (such portion of the CVARs, the "Vested CVARs"), the Reporting Person will be entitled to receive a payment equal to the product of (i) the number of Vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date.

Remarks:

EX-24.1 Power of Attorney